The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Self-citationCharbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308 · cited 1×
“A large body of evidence indicates that DPP-4 inhibitors as a class have a good safety and tolerability profile, with a low incidence of mostly mild-to-moderate adverse events (AEs).([125,127,152-155]) First of all, because of the glucose-dependent nature of their insulinotropic effect, they are associated with very l…”
BackgroundRosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255 · cited 5×
“For vildagliptin, published data are available for more than 20 randomized clinical trials with durations ranging from 12 to 104 weeks, enrolling over 20 000 patients.([81-104]) Overall, vildagliptin at the therapeutic dose of 50mg twice a day lowered HbA1c levels compared with baseline by about 1% as a monotherapy an…”
BackgroundInfluentialOng, K. L., Cheung, B. M. Y., Wong, L. Y. F., Wat, N. M. S., Tan, K. C. B., & Lam, K. S. L. (2008) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.10.007 · Cited by 232
Cited by
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12781 · Cited by 425
Nabeno, M., Akahoshi, F., Kishida, H., Miyaguchi, I., Tanaka, Y., Ishii, S., & Kadowaki, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.010 · Cited by 310
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Metadata
- Authors
- Baetta, R., & Corsini, A.
- Venue
- Drugs
- Published
- 2011-07
- Volume
- 71
- Issue
- 11
- Pages
- 1441-1467
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W20782350
- Cited by
- 209
- References
- 11
- FWCI
- 20.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences. https://app.cochat.ai/papers/10.2165/11591400-000000000-00000
- The paper
- Baetta, R., & Corsini, A. (2011). Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences. Drugs. https://doi.org/10.2165/11591400-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.